$CYBN Providing updates on the CYB003 clinical trials, Cybin's R&D day on February 28 presents a pivotal event for the company and its shareholders, potentially opening doors for the first FDA-approved psychedelic drug for major depressive disorder and presenting substantial growth potential.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.